BioASP Newsletter   Volume 14 December 18 2003

Unsubscribe

 

Research news

AMT confirms efficacy of its LPL gene therapy

Amsterdam Molecular Therapeutics B.V. (AMT), announced that it has confirmed the efficacy of its lipoprotein lipase (LPL) gene therapy in a second animal model. The results, presented at the European Society of Gene Therapy meeting in Edinburgh, confirmed that intramuscular injection of AMT`s LPL gene therapy product in a natural inherited feline model of LPL deficiency induced a greater than 90% reduction of plasma triglyceride levels. AMT`s gene therapy product for the potential treatment of LPL deficiency in humans is an AAV vector expressing the human LPL gene. The triglyceride levels started to decline as early as one week following administration. Triglyceride levels returned to pretreatment levels after 2-4 weeks as a result of the predicted immune response against the human LPL expressed in these animals. It is anticipated that this immune response will be absent in the future treatment of patients. An earlier proof of principle study in mice had also shown positive safety and efficacy. "These results support the company`s decision to accelerate the development of the product and the manufacturing program to support clinical development and further commercialisation is now well underway", Dr. Jan Boesen, CEO of AMT says. These new data are the result of AMT sponsored collaboration between Professor Michael Hayden at the University of British Columbia, Vancouver, Canada and Professor John Kastelein at the Academic Medical Center (AMC) in Amsterdam. AMT licensed the LPL gene therapy technology exclusively from Xenon Genetics Inc, Vancouver, Canada and the AAV technology from the German Cancer Institute at Heidelberg, Germany.


(Source: Amsterdam Molecular Therapeutics, 26-11-2003)
^top^

Scientific advisor Karl Stetter honored with Leeuwenhoek medal

Diversa`s scientific advisor, Karl Stetter, Ph.D., a professor of microbiology at the University of Regensburg, Germany, has been awarded the highly prestigious Leeuwenhoek Medal by the Royal Netherlands Academy of Arts and Sciences (KNAW). The Leeuwenhoek Medal was established in 1875 in honor of scientist Antonie van Leeuwenhoek following his invention of the microscope. The last Leeuwenhoek Medal was granted to Dr. Carl Woese in 1992 for his work discovering the Archaea and defining the "third domain of life," once thought by scientists to be an unusual type of bacteria. Recently, Dr. Stetter has worked extensively with Diversa on the organism Nanoarchaeum equitans, one of his important discoveries, which was described in the Journal Nature in May of 2002. This collaborative effort produced the genome sequence and annotation of Nanoarchaeum equitans, an archaeal microorganism containing the world`s smallest known genome, published in Proceedings of the National Academy of Sciences in October of 2003. The majority of Dr. Stetter`s research has focused on sampling, isolating and characterising archaeal organisms which comprise the third domain of life. The collective work by Dr. Stetter and Diversa to characterise Nanoarchaeum equitans supports theories that Archaea is among the oldest forms of life on earth and has existed for billions of years. Nanoarchaeum appears to be from one of the earliest branches of the Archaea family tree and the proteins of this ancient organism are ancestors of modern enzymes. Their characterisation provides important insights about how enzymes work to catalyse chemical and other processes that may be useful in solving modern challenges.


(Source: PR newswire, 25-11-2003)
(Diversa website)
^top^

QIAGEN and artus announce supply agreement

QIAGEN GmbH and artus GmbH announced that they have entered into a manufacturing and supply agreement. Pursuant to this agreement, artus will integrate QIAGEN`s nucleic acid sample preparation products in its diagnostic systems for use in the detection of a variety of infectious diseases such as SARS, Herpes simplex virus -1/-2, EBV, West Nile Virus, Malaria, Salmonella. These diagnostic solutions employ artus` RealArt amplification technology which is based on the polymerase chain reaction (PCR) technology to which artus holds a non-exclusive license from Roche. The customised solutions will incorporate specific versions of QIAGEN`s sample preparation modules and technologies, including QIAGEN`s QIAamp technology and will be distributed by artus and its distributors in combination with the real-time PCR-based diagnostic solutions under the brand PureArt. QIAGEN`s proprietary nucleic acid sample preparation and handling technologies provide high reliability and efficiency in both, DNA and RNA separation and purification in molecular diagnostics. Following nucleic acid sample extraction, processed samples will be transferred onto artus` RealArt system for amplification and detection. QIAGEN N.V. also announced that it has licensed from Novartis Pharma AG a novel algorithm for the selection of highly functional target sequences for RNA interference applications. More than 3000 randomly designed synthetic siRNA duplexes, against 34 targets were analysed for functionality. Based on this large data set, an automated siRNA sequence selection algorithm was developed. Evaluation of the new algorithm has demonstrated a significant performance improvement over existing design methods. Under the terms of this collaboration QIAGEN obtained a fully paid-up license from Novartis for the worldwide use of this prediction algorithm.


(Source: CNW, 10/15-12-2003)
(Qiagen website)
(Artus website)
^top^

DNAPrint announces forensic eye color results

DNAPrint genomics, Inc. announced progress in developing anthropomorphic genomics testing products to an audience of approximately 500 forensic scientists and detectives at the "DNA ... sporen naar de toekomst II" conference sponsored by The Netherlands Forensic Institute. In 2002, DNAPrint filed a patent application on numerous genetic sequences associated with and predictive for human iris color. The sequences discovered by DNAPrint scientists are known as "markers", and to demonstrate that the predictive value for the markers extends to other sets of samples, DNAPrint initiated an internal validation trial using newly collected samples from across the United States. It was reported in this conference that:

1) Most of the markers originally identified have been validated as generally associated with iris color.

2) The associations for a majority of the markers in the new set of samples are at least as strong as those observed in the set of samples previously studied, and

3) DNAPrint has completed the screening of an additional 11,000 polymorphisms across the human genome to identify and validate a number of additional human iris color markers.

 

Pending the outcome of the trial, a classifier incorporating these markers, DNAPrint will be the first to introduce eye color determination (either Blue or Brown or some other color) from a crime scene sample and the world`s second commercially introduced anthropometric test for the construction of physical profiles from crime scene DNA.


(Source: DNAPrint genomics, 20-11-2003)
(DNAPrint Genomics website)
^top^

New regulation stimulates technological co-operation

As of January 2004 the first the new subsidy ‘Innovatiesubsidie Samenwerkingsprojecten’ will come into operation. The ‘Innovatiesubsidie Samenwerkingsprojecten’ aims at improving the co-operation between research and development (R&D). Companies and public knowledge institutes will  be stimulated and facilitated by this measure to do research and development in both national and international co-operation  agreements. In 2004 the budget will be about 80 million Euro. For research and/or development projects there is a maximum subsidy of 2 million Euros per project. The new measure replaces the existing measures: ‘Technologische Samenwerking’ (TS), ‘Technische Ontwikkelingsprojecten’ (TOP) and the programme ‘Economie, Ecologie & Technologie’ (EET). Technological innovative companies can  send their applications to Senter from 1 March 2004. Senter is an agency of the Ministry of Economic Affairs which implements government policy in the fields of technology, energy, environment, exports and international co-operation.


(Source: Ministerie van Economische Zaken, 10-12-2003)
(Senter website)
(mailto: S.Boitelle@minez.nl)
^top^

SEQUENOM obtains technology patent in Europe

SEQUENOM, Inc. announced that it has obtained a patent from the European Patent Office (EP0815261B1) entitled "DNA Diagnostics Based On Mass Spectrometry." This core patent covers processes for detecting target nucleic acid sequences in a biological sample using mass spectrometry. The patent has been validated in 14 European countries, including Austria, Belgium, Denmark, Finland, France, Germany, Great Britain, Ireland, Italy, The Netherlands, Portugal, Spain, Sweden and Switzerland, and relates to several patents previously issued in the United States. SEQUENOM is a genetics company organised into two distinct business units: SEQUENOM Genetic Systems and SEQUENOM Pharmaceuticals. The two business units combine to capitalise on the Company`s high performance DNA analysis platform, SNP assay portfolio, disease gene discovery programs and extensive DNA sample repository. SEQUENOM is a registered trademark and MassARRAY is a trademark of SEQUENOM, Inc.


(Source: PRNewswire, 11-12-2003)
^top^

Revolutionary weapon for the war on cancer
At the American Society of Hematology meeting in San Diego, CA, Cancer Genetics, Inc. (CGI) launched a new, highly sensitive DNA FISH assay to help diagnose and monitor therapy of chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL). This assay is the first "repeat-free" BCR/ABL four color fluorescent in situ hybridisation (F-FISH) probe and it is CGI`s first product to be introduced into the United States. This F-FISH platform is used to simultaneously detect the t(9;22)(q34.1;q11.2) translocations, associated deletions, variants, and amplifications which occur in CML. The assay design improves sensitivity and specificity, eliminating false positive and false negative results in patient samples. The design of earlier generation probes limited sensitivity and specificity and may not detect deletions and atypical signal patterns arising from complex rearrangements. The F-FISH probe was developed by using CGI`s proprietary Signal Exchange Approach methodology, wherein probes are derived from the regions flanking genes which contain the breakpoints. The Company has filed patent applications covering its proprietary signal segregation approach, signal exchange approach, and repeat removal technology. Cancer Genetics, Inc. probes are labeled with the patented Universal Linkage System (ULS) from KREATECH Biotechnology BV, Amsterdam, The Netherlands.
(Source: Business Wire, 05-12-2003)
(Cancer Genetics website)
^top^

Trial of new investigational AIDS vaccine starts

The Aaron Diamond AIDS Research Center (ADARC), an affiliate of The Rockefeller University, and the International AIDS Vaccine Initiative (IAVI) announced that they have begun a human trial of a new investigational vaccine to prevent HIV/AIDS. The trial is actively seeking healthy volunteers in New York City and Rochester, New York. The trial is designed to evaluate the safety of a new DNA vaccine called ADVAX. The vaccine is designed to stimulate immune responses to prevent people who are uninfected with HIV/AIDS from contracting the disease, and the trial will gather preliminary data on whether ADVAX stimulates these immune responses. The ADVAX vaccine uses synthetic DNA based on a part of the genetic material found in HIV. Unlike traditional vaccines that contain a weakened or killed form of a disease-causing agent, DNA vaccines instead contain only portions of the genetic material. This means ADVAX cannot cause HIV infection or AIDS. The International AIDS Vaccine Initiative) is a global nonprofit scientific organisation working to speed the search for a vaccine to prevent HIV/AIDS. IAVI sponsors research partnerships to develop and test promising vaccine candidates. IAVI`s major financial supporters include among others the Bill & Melinda Gates Foundation; the Rockefeller; the World Bank; the UK Department for International Development, the US Agency for International Development, the Netherlands Ministry of Foreign Affairs, Development Cooperation Ireland, the Ministry of Foreign Affairs of Denmark, the Norwegian Royal Ministry of Foreign Affairs and the Swedish International Development Cooperation Agency.


(IAVI website)
^top^

Bayer Healthcare and Galapagos in collaboration

Galapagos Genomics announced a target discovery collaboration with Bayer HealthCare AG. Within the partnership, the companies will collaborate to discover and validate novel drug targets for Bayer`s disease areas. Galapagos will use its disease biology expertise in combination with its SilenceSelect and FLeXSelect target discovery collections to identify and validate drugable targets. Under the terms of the agreement, Bayer HealthCare has the exclusive right to select validated targets for drug development in return for upfront payments, research funding and milestones. SilenceSelect is a collection of adenoviruses with siRNA based knock-down sequences targeting over 4,000 human drugable genes, where drugable represents those gene classes of most value for pharmaceutical development. FLeXSelect is the mirror collection of adenoviruses with full length genes from the drugable gene classes. These two collections in combination with cellular assays enable the functional discovery of proteins that are directly involved in a specific disease process. In this partnership, Galapagos will design cellular assays in disease areas of interest to Bayer, and subsequently screen the SilenceSelect and FLeXSelect gene collections to identify and validate targets that will proceed into drug discovery by Bayer, the companies state.


(Source: Primezone, 16-12-2003)
(Galapagos website)
^top^

Crucell signs development service agreement

Dutch biotechnology company Crucell N.V. announced that it has signed a service agreement with U.S.-based Progenics Pharmaceuticals, Inc., whereby Crucell will undertake the development of a cell line based on its proprietary PER.C6 technology for the production of a recombinant protein product candidate for Progenics. Under the terms of the agreement, Crucell will receive payments on reaching agreed milestones outlined in the PER.C6 cell line development program. Further financial details were not disclosed. Crucell`s PER.C6 technology offers cell line for the production of a wide range of biologics including recombinant proteins and monoclonal antibodies. Through the PER.C6 technology licensing program, Crucell and DSM Biologics offer pharmaceutical and biotechnology companies a routine cell line development program in which stable PER.C6 cell clones are generated to produce large amounts of the required recombinant protein or monoclonal antibody.


(Crucell website)
^top^

 

BioASP news

EMBOSS included

BioASP has improved the SRS service. Currently we are offering SRS 7.1, including the EM-BOSS application. EMBOSS is a toolkit comprising approximately 100 different applications. It automatically copes with data in a variety of formats and even allows transparent retrieval of sequence data from the web. EMBOSS integrates a range of currently available packages and tools for sequence analysis into a seamless whole.

 

EMBOSS covers:

·          Sequence alignment

·          Rapid database searching with sequence patterns

·          Protein motif identification, including domain analysis

·          Nucleotide sequence pattern analysis, for example to identify CpG islands or repeats.

·          Codon usage analysis for small genomes

·          Rapid identification of sequence patterns in large scale sequence sets

·          Presentation tools for publication

(Source: BioASP, 16-12-2003)
^top^

Improved version of SRS!

SRS (Sequence Retrieval System) is the world’s premier data integration, analysis and display tool for bioinformatic, genomic and related data. With this program biological databases can be searched for information. Using forms the user instructs the system to conduct a specific search in an enormous number of databases, which are updated on a daily basis by BioASP. The results can be used in any of the tools that are incorporated.

 

The previous version of SRS served by BioASP was limited in functionality and therefore we’ve set up a new server to allow the use of deep-linking and (re)use of your results in other applications. The new SRS 7.1 version at BioASP enables:

·                     Fast access to diverse life science data - genetic, protein, cellular, molecular, and clini-cal - for researchers and bioinformaticians

·          Unique ability to perform cross-database queries

·          Rapid string search of large volumes of data

·          Seamless integration of data and analysis tools

 

How to access SRS and Emboss: Go to www.bioasp.nl, Tab Application Services, and use the views to select SRS.

(Source: BioASP, 16-12-2003)
(BioASP website)
^top^

Text mining explores technology and new directions

The Text mining Interest Group, consisting of participants from Collexis, Erasmus MC, KUN, Organon, Semlab, TNO TPD, University Maastricht, have made a joint effort to put the differ-ent text mining technology into a framework. This framework presents the methodologies known, used and developed by the members of the Interest Group, divided into the four categories: document categorising, named entity tagging, fact extraction, collection-wide analysis. The framework provides an overview of relevant literature about the methodologies as well and will be made online as soon as possible.

In the near future the Text mining Interest Group will organise more meetings. One meeting will be set up to explore the possibilities to cooperate in the development and maintenance of Gene Lists. Another meeting will be set up to explore the combination of textmining tools and micro array data. Micro array users will be asked to test the tools which are already made available or will be made available soon by the participants in this group.

The text mining tool of Collexis is already available for academic users on www.bioasp.nl. The CoPubMapper database and program have been generated jointly by researchers from several departments of Organon NV and Erasmus MC.

 

(Source: BioASP, 16-12-2003)
^top^

Will BioASP visit your institute in 2004?

BioASP is on the road visiting research institutes in the Netherlands. The goal of the visits is to introduce the organisation NBIC and to demonstrate the services of BioASP. Last week we were invited in Groningen, Haren and Wageningen.

In Groningen the presentation was given in the academic hospital and despite the fact that the local firewall gave some problems with the demonstration, the audience got a good impres-sion of the kind of services they can get from BioASP. Bioinformatics specialists and some more experienced genomics researchers visited the BioASP road show in Haren and gave some interesting suggestions for the extension of our bioinformatics service package.

In Wageningen we were present at the Food Summit organised by Wageningen Centre for Food Sciences (WCFS). Participants of the symposium were interested in the possibilities of the applications of BioASP for their food research.

These three visits were the last demonstrations of BioASP in 2003, but the road show will continue in 2004. Please contact us if you want BioASP to visit your institute as well.

(Source: BioASP, 16-12-2003)
^top^

GeNeYouS: kick-off symposium for young genomics scientists

Question: what use is knowledge if you can’t share it? Young genomic scientists will take the opportunity to exchange their knowledge on January 20th 2004. This will be the day for Ph.D.-students, postdocs and other young scientists working in genomic research to gather for the first symposium of GeNeYouS, the Genomics Network for Young Scientists. Informative lectures, professional workshops and an interactive forum make up this symposium.

 

The Genomics Network for Scientists (GeNeYouS) is the Dutch network for Ph.D. students, postdocs and young in-company scientists working in the field of genomics. It was initiated by the Netherlands Genomics Initiative and IOP Genomics. The objectives of GeNeYouS are to facilitate interaction between young genomic scientists and to provide them with information on career possibilities, education and (inter-) national exchange possibilities.

It is known that young scientists are faced with a lot of difficult choices during their research, especially when working in the innovative field of genomic research. This is why the symposium is themed: ‘Decisions in genomics’. Relevant aspects and techniques that help in making the right decisions will be discussed. There is also the opportunity to find answers to specific questions.

The symposium is introduced by Wouter Spek – Manager innovation and international affaires at the Netherlands Genomics Initiative, followed by lectures of Ron Kerkhoven – Group  leader of the microarry facility at the Netherlands Cancer Institute – and Peter de Knijf – Head of the Human Genetics department at Leiden University and Medical Center. In addition, Luc Rietveld – Netherlands Organisation for Scientific Research – provides  information on fellowships available for young scientists. In addition there are workshops on a diversity of subjects, e.g. entrepreneurship in genomics, datamining in biological databases and experimental design and analysis. The day is closed with an interactive forum. A detailed program is available online at www.geneyous.nl/symposium.html.

Registration fee for members is €10,- (for non-members this is €50,-). The registration form for the symposium and for a free GeNeYouS membership is available online at www.geneyous.nl. Specific questions can be directed to info@geneyous.nl.

(GeNeYouS website)
^top^

86 million subsidy for NGI initiatives

The omnibus proposal of NGI has been largely honoured by the Dutch government. Four Innovative Clusters and two Technology Centres will together receive 86 million Euro subsidy from the Bsik-scheme

 

The Netherlands Genomics Initiative is very pleased that it has received the subsidy. The overall-proposal which was made by the NGI has hereby been almost fully honoured. The new initiatives will likely commence in the first quarter of 2004.

 

The overall-proposal of the NGI includes four Innovative Clusters (Celiac Disease Consortium, Ecogenomics Consortium, Nutrigenomics Consortium, VIRGO Consortium) and two Technology Centers (BiOrange and the Netherlands Proteomics Centre).

(Source: Genomics, 28-11-2003)
(Genomics website)
^top^

This email-service is a monthly news service from Stichting BioASP aiming to inform participants and other interested parties about national and international developments in bioinformatics, genomics and related topics. For all your requests concerning this news service, please do not hesitate to contact us. Your feedback is always welcome and appreciated.
Stichting BioASP
Postbus 1179
3800 BD AMERSFOORT
the Netherlands
Phone: +31 (0) 33 4 220 209
Fax: +31 (0) 33 4 220 221
E-mail: info@bioasp.nl
Web: www.bioasp.nl
© Electronic distribution within your own organisation is permitted. Otherwise, no part of this publication may be reproduced or disclosed in any other way without prior written permission